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Malaria programs aimed at eliminating Plasmodium falci-
parum (Pf) incorporate active infection detection strategies
to target the subclinical transmission reservoir. Currently
available immunochromatographic lateral flow tests lack
the sensitivity required for Pf malaria elimination; the limit
of detection (LOD) of these rapid diagnostic tests (RDTs) is
above that which is required to identify all transmissible
infections. Malaria RDTs with a significantly improved
LOD would enable more effective elimination interventions
while retaining the critical advantages of low cost, ease of
use, and rural deployment capability. Histidinerich protein
2 (HRP2) is a high-priority target analyte for identifying
individuals at risk of transmitting Pf. HRP2 protein is
secreted by Pf parasites in relatively high concentrations, is
widely conserved among Pf strains, and persists in human
plasma for up to four weeks. These characteristics allow
HRP2 antigen detection even in the absence of circulating
parasites during cyclical sequestration. However, the highly
polymorphic nature of HRP2 makes optimization of RDTs
challenging. Current HRP2-detecting RDT reagents pri-
marily target Type 2 (AHHAHHAAD) and Type 7
(AHHAAD) HRP2 motifs, and independent antibody dis-
covery confirms the most common selection of a C1-13/
PTL-3 antibody conjugate pair yields the best RDT perfor-
mance for the majority of parasite strains. In scenarios
where malaria transmission rapidly decreases, exclusive use
of a diagnostic whose sensitivity varies with the number of
HRP2 epitope repeats can result in single axis evolutionary
pressure, increasing selection for less-detectable parasite
strains. To evaluate the feasibility of developing an HRP2-
based RDT that is highly effective in mass testing and treat-
ment programs, we have assessed the technical characteris-
tics of HRP2 reagents. Our aim is to facilitate the
development of improved malaria HRP2 RDTs by: (1) incor-
porating an understanding of HRP2 structure-function
relationships and their impact on epitope-antibody interac-
tions and adaptation, (2) correlating HRP2 concentration
levels (in pg/mL) with traditional malaria diagnostic metrics
(parasites/mL) for comparative evaluation of tests, and (3)
predicting optimal capture reagents to improve and sustain
HRP2 RDT performance. Based on our ongoing analysis,
we present a product development strategy that combines
capture reagent and platform innovations that can be used
to make highly sensitive Pf malaria RDTs. In addition, we
present criteria for the rational selection of HRP2 protein
and parasite culture controls to support the product life-
cycle from development through commercialization and
scale-up.
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